Gyre Therapeutics (GYRE) Cash from Financing Activities (2010 - 2026)
Gyre Therapeutics (GYRE) reported Cash from Financing Activities of $21000.0 for Q1 2026, down 98.44% year-over-year from $1.3 million in Q1 2025, and down 93.4% quarter-over-quarter from $318000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Cash from Financing Activities data on file, last reported at $21000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $21000.0, down 98.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.1 million (up 726.94% YoY), and the FY2025 annual result was $24.4 million, up 1059.75% from the prior year.
- Cash from Financing Activities slipped to $21000.0 in Q1 2026 per GYRE's latest filing, from $318000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $22.4 million in Q2 2025 and troughed at -$45.0 million in Q3 2022.
- A 5-year average of -$1.1 million and a median of $318000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities slumped 48612.5% in 2023, then jumped 14227.56% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$45.0 million in 2022, then surged by 133.85% to $15.2 million in 2023, then sank by 93.67% to $964000.0 in 2024, then sank by 67.01% to $318000.0 in 2025, then plunged by 93.4% to $21000.0 in 2026.
- Business Quant data shows GYRE's Cash from Financing Activities at $21000.0 in Q1 2026, $318000.0 in Q4 2025, and $365000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Sep 30, 2025 | 365,000.00 |
| Sep 30, 2025 | 365,000.00 |
| Jun 30, 2025 | 22.35 Mn |
| Jun 30, 2025 | 22.35 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 964,000.00 |
| Dec 31, 2024 | 964,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 658,000.00 |
| Mar 31, 2024 | 658,000.00 |
| Dec 31, 2023 | 15.24 Mn |
| Dec 31, 2023 | 15.24 Mn |